Skip to main content
. Author manuscript; available in PMC: 2024 Sep 3.
Published in final edited form as: Target Oncol. 2023 Jun 26;18(4):601–610. doi: 10.1007/s11523-023-00980-8

Fig. 1.

Fig. 1

Cohort diagram; 103 patients receiving immune checkpoint inhibitor (ICI) therapy met laboratory thresholds for grade 2 immune related hepatitis (irH) and had an accompanying provider documented diagnosis of irH; 97 cases were included in the analysis and matched with controls based on age, sex, time of ICI initiation and length of follow-up. ECOG Eastern Cooperative Oncology Group